John McGrane

406 total citations
29 papers, 139 citations indexed

About

John McGrane is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, John McGrane has authored 29 papers receiving a total of 139 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 6 papers in Obstetrics and Gynecology. Recurrent topics in John McGrane's work include Renal cell carcinoma treatment (9 papers), Endometrial and Cervical Cancer Treatments (6 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). John McGrane is often cited by papers focused on Renal cell carcinoma treatment (9 papers), Endometrial and Cervical Cancer Treatments (6 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). John McGrane collaborates with scholars based in United Kingdom, Netherlands and Germany. John McGrane's co-authors include Ruud L.M. Bekkers, Khadra Galaal, J Palmer, Joseph Mathew, Johanna M.A. Pijnenborg, Austin G. Acheson, Catherine Walter, Hannah Donkers, James Wheeler and Ingfrid S. Haldorsen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and British Journal of Cancer.

In The Last Decade

John McGrane

24 papers receiving 138 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John McGrane United Kingdom	7	75	50	28	25	22	29	139
Nicolas Delanoy France	8	90 1.2×	101 2.0×	27 1.0×	18 0.7×	21 1.0×	32	208
Keiko Nemoto Murofushi Japan	8	55 0.7×	93 1.9×	73 2.6×	17 0.7×	32 1.5×	33	182
Xin Song China	9	54 0.7×	42 0.8×	40 1.4×	30 1.2×	8 0.4×	28	226
Sushmita Rath India	8	83 1.1×	40 0.8×	33 1.2×	5 0.2×	19 0.9×	25	143
Muhammad O. Awiwi United States	8	50 0.7×	43 0.9×	28 1.0×	6 0.2×	13 0.6×	21	117
Felicia Roncolato Australia	8	133 1.8×	55 1.1×	43 1.5×	59 2.4×	42 1.9×	31	247
Lorraine Walsh Canada	5	36 0.5×	48 1.0×	59 2.1×	16 0.6×	39 1.8×	7	146
Ryotaro Ohkuma Japan	9	126 1.7×	50 1.0×	18 0.6×	27 1.1×	8 0.4×	15	174
Jérémie Tordo France	7	38 0.5×	22 0.4×	22 0.8×	6 0.2×	24 1.1×	24	116
D. Purdie United States	8	116 1.5×	52 1.0×	20 0.7×	32 1.3×	8 0.4×	23	214

Countries citing papers authored by John McGrane

Since Specialization

Citations

This map shows the geographic impact of John McGrane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John McGrane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John McGrane more than expected).

Fields of papers citing papers by John McGrane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John McGrane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John McGrane. The network helps show where John McGrane may publish in the future.

Co-authorship network of co-authors of John McGrane

This figure shows the co-authorship network connecting the top 25 collaborators of John McGrane. A scholar is included among the top collaborators of John McGrane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John McGrane. John McGrane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McCarthy, Elizabeth, Amy L. Chadwick, J.J. Soto Castillo, et al.. (2025). A multi-centre review of the use of adjuvant pembrolizumab for renal cell carcinoma.. Journal of Clinical Oncology. 43(5_suppl). 484–484.

Charnley, Natalie, Kate Fife, Daniel Y.C. Heng, et al.. (2025). Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review. Cancer Treatment Reviews. 140. 103024–103024.

McGrane, John, Amarnath Challapalli, Alison Clayton, et al.. (2024). Real world, multicentre patterns of treatment and survival in metastatic renal cell carcinoma with the UK Renal Oncology Collaborative (UK ROC): Is it time to look favourably on first‐line immunotherapy containing combinations in all IMDC groups?. Cancer Medicine. 13(12).

Jones, Robert J., Simon J. Crabb, Mark Linch, et al.. (2024). Systemic anticancer therapy for urothelial carcinoma: UK oncologists’ perspective. British Journal of Cancer. 130(6). 897–907. 12 indexed citations

Krell, Jonathan, John McGrane, Andreas D. Hartkopf, et al.. (2024). Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression. Future Oncology. 20(40). 3409–3419. 1 indexed citations

Nathan, Paul, Natalie Charnley, John McGrane, et al.. (2024). A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Outcomes at 36 months post treatment initiation.. Journal of Clinical Oncology. 42(4_suppl). 386–386. 2 indexed citations

McGrane, John, et al.. (2023). ‘Godrevy Project’: virtual reality for symptom control and well-being in oncology and palliative care – a non-randomised pre-post interventional trial. SHILAP Revista de lepidopterología. 2(1). e000160–e000160. 3 indexed citations

Nathan, Paul, Natalie Charnley, John McGrane, et al.. (2023). A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): 24-month interim results.. Journal of Clinical Oncology. 41(6_suppl). 631–631. 2 indexed citations

Krell, Jonathan, John McGrane, Anjana Anand, et al.. (2022). 2022-RA-1505-ESGO Ovarian cancer retrospective European (O’CaRE) observational study: analysis of first-line (1L) outcomes in patients with ovarian cancer (OC) stratified by number of risk factors for progression. International Journal of Gynecological Cancer. 32. A344–A344. 1 indexed citations

10.

Challapalli, Amarnath, John McGrane, Sarah Kingdon, et al.. (2022). 1457P A UK multicentre retrospective review of metastatic renal cell carcinoma (mRCC) patients (pts) outcomes with brain metastases (BM) in the modern era. Annals of Oncology. 33. S1211–S1211. 2 indexed citations

11.

Challapalli, Amarnath, John McGrane, Sarah Kingdon, et al.. (2022). 1463P Patterns of care and outcomes of metastatic renal cell carcinoma (mRCC) patients (pts) with bone metastases (BM): A UK multicenter review. Annals of Oncology. 33. S1215–S1215.

12.

Donkers, Hannah, Casper Reijnen, Khadra Galaal, et al.. (2022). Defining the Optimal Treatment Strategy in Patients With Uterine Serous Carcinoma. Clinical Oncology. 35(2). e199–e205. 2 indexed citations

13.

McGrane, John, et al.. (2021). 745P Ovarian Cancer Retrospective European (O’CaRE) observational study to assess burden of disease and time to next treatment in real-world clinical practice: Results from the United Kingdom (UK). Annals of Oncology. 32. S741–S741. 1 indexed citations

14.

Donkers, Hannah, Kristine E. Fasmer, John McGrane, et al.. (2021). The role of sarcopenic obesity in high‐grade endometrial cancer. International Journal of Gynecology & Obstetrics. 154(2). 248–255. 8 indexed citations

15.

Rowe, Michael, et al.. (2021). An analysis of survival in patients with castrate-resistant prostate cancer receiving enzalutamide with treatment breaks. Journal of Clinical Urology. 15(3). 257–263. 1 indexed citations

16.

Rimmer, Y., Amy Law, Darren Leaning, et al.. (2019). National small cell bladder cancer audit: Results from 26 UK institutions. Annals of Oncology. 30. v373–v373. 1 indexed citations

17.

Smits, Anke, John McGrane, Alberto Lopes, et al.. (2017). Radiation-related toxicities and outcomes in endometrial cancer: are obese women at a disadvantage?. International Journal of Clinical Oncology. 22(5). 945–953. 7 indexed citations

18.

McGrane, John, et al.. (2017). Significance of Anemia in Outcomes After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. Clinical Colorectal Cancer. 16(4). 381–385. 21 indexed citations

19.

Thomson, Alastair, John McGrane, Joseph Mathew, et al.. (2016). Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes. British Journal of Cancer. 114(7). 793–800. 29 indexed citations

20.

McGrane, John, et al.. (2016). Metastatic spinal cord compression from basal cell carcinoma of the skin treated with surgical decompression and vismodegib: case report and review of Hedgehog signalling pathway inhibition in advanced basal cell carcinoma. Clinical and Experimental Dermatology. 42(1). 80–83. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact